Chemoradiation for esophageal cancer: Institutional experience with three different regimens

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 4, 2011, Pages 343-349

  Courrech Staal, Ewout F W ^a   Aleman, Berthe M P ^a   Van Velthuysen, Marie Louise F ^a   Cats, Annemieke ^a   Boot, Henk ^a   Jansen, Edwin P M ^a   Van Coevorden, Frits ^a   Van Sandick, Johanna W ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

chemoradiation; combined modality therapy; esophageal cancer; esophagectomy; tumor regression grade

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; ESOPHAGITIS; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUTROPENIA; RADIATION INDUCED EMESIS; RADIATION SICKNESS; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; RADIOTHERAPY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79961166770     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181dbbafe     Document Type: Article

References (26)

1. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/ distal esophagus: Five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992-1000. (Pubitemid 350179188)
2. Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treatment of locally advanced esophageal cancer: A systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257-1264. (Pubitemid 46440778)
3. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol. 2007;8:226-234. (Pubitemid 46291702)
4. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538-543. (Pubitemid 36627845)
5. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168. (Pubitemid 46640561)
6. Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys. 2001;49:657-664. (Pubitemid 32112193)
7. Liao Z, Zhang Z, Jin J, et al. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004;60:1484-1493. (Pubitemid 39601865)
8. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol. 2005;6:659-668. (Pubitemid 41222756)
9. Mariette C, Piessen G, Lamblin A, et al. Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg. 2006;93:1077-1083. (Pubitemid 44343504)
10. van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study. Br J Cancer. 2006;94:1389-1394. (Pubitemid 43772271)
11. Wang H, Ryu J, Gandara D, et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007;2:153-157. (Pubitemid 47181345)
12. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18:1458-1464. (Pubitemid 30205391)
13. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. Hoboken, NJ: John Wiley & Sons; 2002.
14. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologic correlations. Cancer. 1994;73:2680-2686. (Pubitemid 24166250)
15. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335:462-467. (Pubitemid 26269945)
16. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167. (Pubitemid 27306287)
17. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313. (Pubitemid 32112841)
18. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317. (Pubitemid 46218723)
19. Choy H, Devore RF III, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys. 2000;47:931-937. (Pubitemid 30345590)
20. van Heijl M, van Lanschot JJ, Koppert LB, et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg. 2008;8:21.
21. Pignon JP, Bourhis J, Domenge C, et al; MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: Three meta-analyses of updated individual data: Meta-Analysis of Chemotherapy on head and neck cancer. Lancet. 2000;355:949-955. (Pubitemid 30148259)
22. Hoebers FJ, Heemsbergen W, Balm AJ, et al. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother Oncol. 2007;85:42-47. (Pubitemid 47570059)
23. Brucher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: Results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963-971. (Pubitemid 39462527)
24. Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007; 245:707-716. (Pubitemid 46684100)
25. Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response. Ann Surg Oncol. 2008;15:2894-2902.
26. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160. (Pubitemid 39303827)